Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Diclofenac sodium 50mg gastro-resistant tablets
1001010C0AAAEAE
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 48,783 |
|
Diclofenac sodium 3% gel
1308010W0AAAAAA
|
Diclofenac sodium (Actinac Keratosis) | Diclofenac sodium | Skin | 22,781 |
|
Solaraze 3% gel
1308010W0BBAAAA
|
Solaraze | Diclofenac sodium | Skin | 21,032 |
|
Diclofenac 100mg suppositories
1001010C0AAACAC
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 14,412 |
|
Diclofenac sodium 75mg modified-release capsules
1001010C0AAAWAW
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,539 |
|
Diclofenac 50mg suppositories
1001010C0AAAUAU
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,415 |
|
Diclofenac sodium 75mg modified-release tablets
1001010C0AAALAL
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 7,172 |
|
Diclofenac sodium 1% gel
1003020U0AAAKAK
|
Diclofenac sodium (Topical) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 6,640 |
|
Diclofenac sodium 25mg gastro-resistant tablets
1001010C0AAADAD
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 4,686 |
|
Diclofenac sodium 75mg gast res MR caps
1001010C0AAARAR
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 4,591 |
|
Diclofenac sodium 75mg gast res / Misoprostol 200microg tab
1001010C0AAAXAX
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 2,328 |
|
Diclofenac sodium 50mg gast res / Misoprostol 200microg tab
1001010C0AAAMAM
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1,922 |
|
Arthrotec 75 gastro-resistant tablets
1001010C0BLABAX
|
Arthrotec | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1,903 |
|
Diclofenac sodium 100mg modified-release capsules
1001010C0AAANAN
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1,715 |
|
Diclofenac sodium 100mg modified-release tablets
1001010C0AAAFAF
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1,600 |
|
Arthrotec 50 gastro-resistant tablets
1001010C0BLAAAM
|
Arthrotec | Diclofenac sodium | Musculoskeletal and Joint Diseases | 1,436 |
|
Diclofenac 25mg suppositories
1001010C0AAATAT
|
Diclofenac sodium (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 772 |
|
Diclofenac 140mg medicated plasters
1003020U0AAAJAJ
|
Diclofenac sodium (Topical) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 674 |
|
Diclomax SR 75mg capsules
1001010C0BMABAW
|
Diclomax Retard | Diclofenac sodium | Musculoskeletal and Joint Diseases | 554 |
|
Voltarol 100mg suppositories
1001010C0BBADAC
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 483 |
|
Motifene 75mg modified-release capsules
1001010C0BPAAAR
|
Motifene | Diclofenac sodium | Musculoskeletal and Joint Diseases | 452 |
|
Diclofenac 0.1% eye drops 0.3ml unit dose preservative free
1108020A0AAAAAA
|
Diclofenac sodium (Eye) | Diclofenac sodium | Eye | 355 |
|
Diclofenac 0.1% eye drops
1108020A0AAACAC
|
Diclofenac sodium (Eye) | Diclofenac sodium | Eye | 303 |
|
Voltarol ONE A DAY Muscle Pain Relief 140mg plaster
1003020U0BJAAAJ
|
Voltarol (Topical) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 291 |
|
Voltarol 50mg suppositories
1001010C0BBAJAU
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | 269 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.